Compare Deckers Outdoor Corp (DECK) vs Davita Inc (DVA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Deckers Outdoor Corp vs Davita Inc — how do they compare? Deckers Outdoor Corp trades at $82.98 (market cap $11.24B), while Davita Inc trades at $175.04 (market cap $11.29B). The key difference: Deckers Outdoor Corp and Davita Inc are close in size by market cap, and Davita Inc is trading nearer its 52-week high, Deckers Outdoor Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Deckers Outdoor Corp for 71 Days and Davita Inc for 113 Days on average.
| DECK | DVA | |
|---|---|---|
Market Cap | $11.24B | $11.29B |
Volume | 3,010,945 | 582,204 |
Sector | Consumer Cyclical | Health |
52-Week High | $120.94 | $240.96 |
52-Week Low | $77.51 | $103.87 |
Typical Hold Time | 71 Days | 113 Days |
Enterprise Value | $10.11B | $24.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DECK trades at $80.38, down 1.57% on the day, with a neutral technical signal and strong fundamentals. Revenue grew to $4.99B in 2025, net income reached $966.09M, and profitability metrics like ROE of 42.56% are robust. Recent earnings beats and analyst upgrades reflect optimism, while cash flow trends show operational strength despite a projected net outflow in 2026.
The outlook is positive given valuation discounts (P/E 11.74), consistent earnings outperformance, and bullish analyst targets averaging $117.13. Risks include reliance on key brands HOKA and UGG, competitive pressures, and potential macroeconomic headwinds affecting consumer discretionary spending.
DaVita (DVA) trades at $176.78, down 2.01% today, showing technical bearish signals with price near key support at $175. Fundamentally, the company demonstrates solid earnings performance with three consecutive quarterly beats and attractive valuation metrics including a P/E of 14.98 and P/S of 0.88. Recent expansion of value-based care partnerships with Humana positions the company for continued growth in kidney care services.
The stock presents a compelling value opportunity with analyst consensus target of $235.67 offering 33% upside potential, though investors face risks from regulatory pressures and narrowing profit margins. Warren Buffett's significant ownership (45%) and institutional buying activity provide confidence, but the bearish technical outlook and mixed analyst ratings (43% Buy, 52% Hold) suggest cautious optimism is warranted.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Deckers Outdoor Corp
Deckers Outdoor Corp designs and sells casual and performance footwear, apparel, and accessories. Primary brands include UGG, Teva, and Sanuk. The company distributes Most of its products through its wholesale business, but it also has a substantial direct-to-consumer business with its company-owned retail stores and websites. Most sales are in the United States, although the company also has retail stores and distributors throughout Europe, Asia, Canada, and Latin America. Deckers sources its products from independent manufacturers primarily in Asia.
Read more on DECK →About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →
